AbbVie stock trades at EUR 249.65, P/ E 78.22

Published on 10/12/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EUR 249.65 was AbbVie's price on October 12, 2026, versus EUR 245.70. AbbVie stock traded 1.60 percent higher, with P/E 78.22.

Key points in brief

AbbVie stock traded at EUR 249.65 at Lang & Schwarz on October 12, 2026, 1.60 percent above the October 9 Xetra close of EUR 245.70.
The EUR 442.8 billion market capitalization and P/E of 78.22 place AbbVie among the largest listed drugmakers.
Cantor Fitzgerald raised its price target from USD 285.00 to USD 290.00 on October 8, 2026, while keeping an Overweight rating.
AbbVie is scheduled to report third-quarter 2026 results on October 30, 2026, before the US market opens.

Extreme Makroaufnahme irisierender pharmazeutischer Kristallstrukturen unter polarisiertem Mikroskoplicht — AbbVie Inc. US00287Y1091 Makrofotografie irisierender kristalliner Molekülstrukturen unter polarisiertem Mikroskoplicht Biopharma Forschung, Illustration mit AI erstellt.

AbbVie stock (ISIN US00287Y1091) was trading at EUR 249.65 at Lang & Schwarz on October 12, 2026 at 4:39 p.m. CEST, 1.60 percent above the Xetra close of October 9, 2026 at EUR 245.70. The move places the euro quote EUR 0.95 below its 52-week high of EUR 250.60.

Price stays near yearly high

The 52-week range for the Xetra quote runs from EUR 162.85 to EUR 250.60, based on the latest market data. At EUR 249.65, the stock stands 0.38 percent below that high, a narrow gap that makes the next earnings release a direct calendar reference for the valuation.

The US listing was trading at USD 279.04 on October 12, 2026 at 10:47 a.m. ET. Its market capitalization was EUR 442.8 billion on the German quote, while the price-to-earnings ratio was 78.22 and the dividend yield was 2.00 percent.

Valuation and analyst targets

Cantor Fitzgerald raised its price target for AbbVie from USD 285.00 to USD 290.00 on October 8, 2026, and kept an Overweight rating, as Markets Insider reported. The target change gives the analyst view a separate benchmark from the current euro quote.

Stock Titan reported that AbbVie will announce third-quarter 2026 results on October 30, 2026, before the market opens. The scheduled report is the next major dated test for revenue, earnings and the company outlook.

Comparison with peers

AbbVie Inc.: plus 1.60 percent, P/E 78.22, market capitalization EUR 442.8 billion
Bristol-Myers Squibb Company (NYSE, USD): minus 3.23 percent, P/E 12.58, market capitalization USD 116.9 billion
Johnson & Johnson (NYSE, USD): plus 0.34 percent, P/E 30.40, market capitalization USD 632.2 billion

What the calendar adds

AbbVie combines a quote close to its 52-week high with a scheduled third-quarter report and a higher Cantor Fitzgerald target. The comparison also shows a wide valuation spread across large pharmaceutical stocks, with AbbVie's P/E above the figures shown for Bristol-Myers Squibb and Johnson & Johnson.

The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.